PRECISE-DAPT score: Difference between revisions
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
PRECISE-DAPT score is a validated risk assessment tool designed to predict the risk of bleeding associated with dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor among patients who are treated with coronary stenting. | |||
==PRECISE-DAPT score== | |||
PRECISE-DAPT score is a validated risk assessment tool designed to predict the risk of bleeding associated with dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor among patients who are treated with coronary stenting.<ref name="Costavan Klaveren2017">{{cite journal|last1=Costa|first1=Francesco|last2=van Klaveren|first2=David|last3=James|first3=Stefan|last4=Heg|first4=Dik|last5=Räber|first5=Lorenz|last6=Feres|first6=Fausto|last7=Pilgrim|first7=Thomas|last8=Hong|first8=Myeong-Ki|last9=Kim|first9=Hyo-Soo|last10=Colombo|first10=Antonio|last11=Steg|first11=Philippe Gabriel|last12=Zanchin|first12=Thomas|last13=Palmerini|first13=Tullio|last14=Wallentin|first14=Lars|last15=Bhatt|first15=Deepak L|last16=Stone|first16=Gregg W|last17=Windecker|first17=Stephan|last18=Steyerberg|first18=Ewout W|last19=Valgimigli|first19=Marco|title=Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials|journal=The Lancet|volume=389|issue=10073|year=2017|pages=1025–1034|issn=01406736|doi=10.1016/S0140-6736(17)30397-5}}</ref> | |||
[Name of the Score] was invented by (Author) et al in (year), and has been externally validated in (other populations/subsequent studies).(add references) | [Name of the Score] was invented by (Author) et al in (year), and has been externally validated in (other populations/subsequent studies).(add references) | ||
| Line 14: | Line 16: | ||
[Name of the Score] is a (clinical prediction rule) devised to assess the severity of (acute pancreatitis/other disease) among (hospitalized patients/healthy individuals/other population) in the (outpatient/inpatient/surgical/medical/emergency room) setting. | [Name of the Score] is a (clinical prediction rule) devised to assess the severity of (acute pancreatitis/other disease) among (hospitalized patients/healthy individuals/other population) in the (outpatient/inpatient/surgical/medical/emergency room) setting. | ||
[Name of the Score] is a (decision tool) designed to assist the decision-making pertaining to the (risk/benefit) of (antiplatelet/antithrombotic/other treatment) for (acute coronary syndrome/other conditions) among (hospitalized patients/healthy individuals/other population). | [Name of the Score] is a (decision tool) designed to assist the decision-making pertaining to the (risk/benefit) of (antiplatelet/antithrombotic/other treatment) for (acute coronary syndrome/other conditions) among (hospitalized patients/healthy individuals/other population). | ||
| Line 26: | Line 26: | ||
==Interpretation== | ==Interpretation== | ||
* Score | * Score < 25: | ||
* Score | * Score ≥ 25: Higher risk of thrombotic-ischemic events and a significantly higher risk of death (particularly bleeding related), MI and major bleeding | ||
==See also== | ==See also== | ||
| Line 36: | Line 35: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Latest revision as of 13:51, 25 October 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Synonyms and keywords: PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy;
Overview
PRECISE-DAPT score is a validated risk assessment tool designed to predict the risk of bleeding associated with dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor among patients who are treated with coronary stenting.
PRECISE-DAPT score
PRECISE-DAPT score is a validated risk assessment tool designed to predict the risk of bleeding associated with dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor among patients who are treated with coronary stenting.[1]
[Name of the Score] was invented by (Author) et al in (year), and has been externally validated in (other populations/subsequent studies).(add references)
[Name of the Score] is a (risk assessment tool/risk stratification scheme) designed to assess the (30-day/5-year) risk of (bleeding/ischemia/other end point) associated with (antiplatelet/antithrombotic/other treatment) among patients with (coronary heart disease/heart failure/other condition).
[Name of the Score] is a (clinical prediction rule) devised to assess the severity of (acute pancreatitis/other disease) among (hospitalized patients/healthy individuals/other population) in the (outpatient/inpatient/surgical/medical/emergency room) setting.
[Name of the Score] is a (decision tool) designed to assist the decision-making pertaining to the (risk/benefit) of (antiplatelet/antithrombotic/other treatment) for (acute coronary syndrome/other conditions) among (hospitalized patients/healthy individuals/other population).
[Name of the Score] Calculator
Shown below is the calculator for [Name of the Score] (check all the boxes that apply):
(insert widget here) {{#widget:Widget_Name}}
Interpretation
- Score < 25:
- Score ≥ 25: Higher risk of thrombotic-ischemic events and a significantly higher risk of death (particularly bleeding related), MI and major bleeding
See also
References
- ↑ Costa, Francesco; van Klaveren, David; James, Stefan; Heg, Dik; Räber, Lorenz; Feres, Fausto; Pilgrim, Thomas; Hong, Myeong-Ki; Kim, Hyo-Soo; Colombo, Antonio; Steg, Philippe Gabriel; Zanchin, Thomas; Palmerini, Tullio; Wallentin, Lars; Bhatt, Deepak L; Stone, Gregg W; Windecker, Stephan; Steyerberg, Ewout W; Valgimigli, Marco (2017). "Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials". The Lancet. 389 (10073): 1025–1034. doi:10.1016/S0140-6736(17)30397-5. ISSN 0140-6736.